News about Global Pharma

Telix Plans to Add FAP-Targeting Candidates to Theranostic Pipeline

Telix has entered into asset purchase and exclusive worldwide in-licence agreements for a suite of clinically validated FAP-targeting therapeutic and precision medicine (diagnostic) radiopharmaceutical candidates.

Global Pharma | 19/11/2024 | By Aishwarya |  756

Indegene Inaugurates New Center in Hyderabad to Empower Global Business

This move aligns with Indegene’s purpose to enable healthcare organizations to be future-ready by combining deep medical expertise with fit-for-purpose technology.

Global Pharma | 18/11/2024 | By Aishwarya |  741

AbbVie Receives European Commission Approval of ELAHERE

ELAHERE is the first and only folate receptor alpha (FR?)-directed antibody drug conjugate (ADC) medicine approved in the European Union (EU), as well as Iceland, Liechtenstein, Norway, and Northern Ireland.

Global Pharma | 18/11/2024 | By Aishwarya |  547

Ascentage Pharma Gets NDA Approval for Bcl-2 Inhibitor Lisaftoclax

This NDA is based on results from a pivotal registrational Phase II study in China (APG2575CC201) that evaluated the efficacy and safety of lisaftoclax in patients with r/r CLL/SLL.

Global Pharma | 18/11/2024 | By Aishwarya |  569

Pulmatrix Proposes Merger Deal with Cullgen

Cullgen utilizes its proprietary technology platform, uSMITE™, featuring novel E3 ligands, to build the next generation of targeted protein degraders and degrader-antibody conjugates (DACs).

Global Pharma | 16/11/2024 | By Aishwarya |  510

DBT, BIRAC Unveil Webinar Series on Biomanufacturing and Biofoundry Initiative

The webinar series aims to bring together industry leaders, scientists, researchers, start-ups, and SMEs to discuss key developments in biomanufacturing.

Global Pharma | 16/11/2024 | By Aishwarya |  336

Alembic Pharmaceuticals Gets USFDA Final Approval for Ivabradine Tablets

Ivabradine is a hyperpolarization-activated cyclic nucleotide-gated channel blocker indicated to reduce the risk of hospitalization for worsening heart failure in adult patients with stable, symptomatic chronic heart failure with reduced left ventricular ejection fraction.

Global Pharma | 15/11/2024 | By Aishwarya |  440

Azenta Receives Regulatory Approval for Clinical Long-Read WGS Test

Performed within GENEWIZ from Azenta Life Sciences' CLIA-certified and CAP-accredited state-of-the-art clinical genomics laboratory, the test enables precise detection of a range of complex genomic alterations that are features of many rare diseases and undetectable by traditional approaches.

Global Pharma | 15/11/2024 | By Aishwarya |  388

Flare Therapeutics Partners with Roche Accelerate Drug Discovery in Oncology

This partnership will leverage Flare Therapeutics' proteomic and mass spectrometry platform and expertise, powered by its proprietary library of electrophilic compounds, to discover novel small molecule drugs aimed at previously undrugged transcription factor targets in oncology.

Global Pharma | 14/11/2024 | By Aishwarya |  751

AstraZeneca Announces Investment of USD 3.5 Billion in R&D in US

AstraZeneca’s expanding footprint in the US includes, a state-of-the-art R&D centre in Kendall Square, Cambridge, Massachusetts, a next generation manufacturing facility for biologics in Maryland, cell therapy manufacturing capacity on the West and East Coasts and a specialty manufacturing in Texas.

Global Pharma | 14/11/2024 | By Aishwarya |  390